GE Healthcare has introduced the SIGNA Experience, a ‘platform of four synergistic technologies that help users through the diagnostic journey. This integrated platform works together to ensure the smoothest magnetic resonance imaging (MRI) scanning experience possible for the physician, technologists of all skill levels, and the patient.’
The four technologies are:
SIGNA One is the next-generation imaging software platform supporting an elegant, intuitive user interface, designed to offer high-quality magnetic resonance (MR) imaging.
AI/Deep-learning solutions: Pioneering, deep-learning AI applications, such as AIR Recon DL for improved signal-to-noise ratio (SNR), image sharpness and shorter scan time. To date, an estimated 5.5 million patients globally have been scanned with AIR Recon DLi.
Workflow solutions: Automated, intelligent workflow technologies that include AIR x and AIR Touch, which guide technologists to help make an MRI scan setup better, faster, and easier.
AIR Coils: Industry-leading, transformative technology in coils, which are flexible, lightweight, and comfortable, enabling total freedom in coil positioning and handling during an MRI scan.
As per the press release, the benefits of this user interface are that it enables:
Intuitive workflow for all experience levels and virtually no learning curve. Technologists can keep track of progress at a glance with useful visual reminders, showing them where they are at any point within the scanning process.
Efficiency with visually assisted highlighted fields to guide technologists step-by-step, making the process flow easily; and flexibility in design to accommodate for future expansion in AI and workflows.
Simplification with an easy-to-use express mode which only requires a few clicks to complete an examination, helping to streamline workflow and optimize throughput.
Intelligent automation that highlights the most likely action following a scan.
SIGNA One is currently commercially available on SIGNA Prime.
Join the HealthXL Webinar on ‘The Potential of AI in Drug Discovery’ on 6th December. Click here to Request to Join.
Click here to read the complete press release.